New studies: Vi-DT vaccine is safe and immunogenic, with booster dosing potentially eliciting long-term immune responses

January 27, 2022 – SEOUL, Republic of Korea – A new study shows that late booster dosing with Vi polysaccharide conjugated with diphtheria toxoid (Vi-DT), one of the typhoid conjugate vaccines (TCVs), at 27.5 months post-first dose is safe and elicits robust immune responses in […]

IVI and NVI partner for collaborative vaccine R&D and capacity building

  IVI and the National Vaccine Institute (NVI) of Thailand signed a Definitive Agreement to strengthen their collaborative partnership   January 20, 2022 – SEOUL, Republic of Korea – The International Vaccine Institute (IVI) and the National Vaccine Institute (NVI) of Thailand signed a Definitive […]

IVI and SK bioscience Complete Recruitment for Phase III Clinical Trial of SKBS’ COVID-19 Vaccine

Recruitment of global Phase III clinical trial of ‘GBP510’ completed, with vaccine expected to be authorized in the first half of 2022 A booster dose study is concurrently being planned to bring additional vaccine to the global COVID-19 vaccine market   January 19, 2022 SEOUL, […]

IVI, ADB SEADS, IPK, ICARS, and the Danish Embassy in Korea launch webinar on combatting antimicrobial resistance

    The webinar “Curbing the Invisible Pandemic: Effective Solutions to Collectively Combat Antimicrobial Resistance” was held on December 7, 2021   December 7, 2021 — The International Vaccine Institute (IVI), Asian Development Bank Southeast Asia Development Solutions (ADB SEADS), Institut Pasteur Korea (IPK), the […]